英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

clanship    
n. 族阀,氏族的团结,爱党心,氏族制度

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • What is LIBTAYO® (cemiplimab-rwlc) | Advanced NSCLC
    LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat adults with a type of lung cancer called non–small cell lung cancer (NSCLC) that has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung
  • How Libtayo Works for Non-Small-Cell Lung Cancer - WebMD
    Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of EGFR, ALK
  • Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by . . .
    Libtayo may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, OR your lung cancer has spread to other areas of your body (metastatic lung cancer), AND your tumor tests positive for high "PD-L1", AND your tumor
  • Cemiplimab (Libtayo) - NCBI Bookshelf - National Center for . . .
    CADTH recommends that Libtayo in combination with platinum-based chemotherapy be reimbursed by public drug plans for the first-line treatment of adults with non–small cell lung cancer (NSCLC) whose tumours have no EGFR, ALK, or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or for those with metastatic NSCLC, if
  • Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung . . .
    INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
  • LIBTAYO works with your immune system to help treat advanced NSCLC
    LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor does
  • Diagnosis and Treatment of ALK Positive NSCLC - PMC
    Shaw AT, Kim DW, Mehra R, et al Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer N Engl J Med 2014;370(13):1189–1197 doi: 10 1056 NEJMoa1311107 [PMC free article] [Google Scholar] 33 Friboulet L, Li N, Katayama R, et al The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
  • ALK TKI therapy in patients with ALK-positive non-small cell lung . . .
    We identified 56 articles involving patients with ALK-positive non-small cell lung cancer (NSCLC) and brain metastases (BM) treated with ALK TKIs published between January 2000 and June 2021 In first-line settings, central nervous system response rates in clinical trials with alectinib (86-94%), brigatinib (67-78%), and lorlatinib (42-82%
  • A comprehensive evaluation of ALK inhibitors in the first-line . . .
    Lung cancer ranks among the leading malignancies in terms of both incidence and mortality Non-small cell lung cancer (NSCLC) constitutes approximately 80 % of all lung cancer cases, with ALK-positive NSCLC representing a subset that ranges from 3 % to 7 % of these cases 1 During the past two decades, the therapeutic landscape for NSCLC has transitioned from cytotoxic chemotherapy to
  • Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by . . .
    Adults with a type of lung cancer called NSCLC: Libtayo may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread





中文字典-英文字典  2005-2009